TY - JOUR T1 - Evidence for Pleiotropic Signaling at the Mouse β<sub>3</sub>-Adrenoceptor Revealed by SR59230A [3-(2-Ethylphenoxy)-1-[(1,<em>S</em>)-1,2,3,4-tetrahydronapth-1-ylamino]-2<em>S</em>-2-propanol Oxalate] JF - Journal of Pharmacology and Experimental Therapeutics JO - J Pharmacol Exp Ther SP - 1064 LP - 1074 DO - 10.1124/jpet.104.076901 VL - 312 IS - 3 AU - Dana S. Hutchinson AU - Masaaki Sato AU - Bronwyn A. Evans AU - Arthur Christopoulos AU - Roger J. Summers Y1 - 2005/03/01 UR - http://jpet.aspetjournals.org/content/312/3/1064.abstract N2 - This study examines the action of the β3-adrenoceptor antagonist SR59230A [3-(2-ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanoloxalate] at cloned mouse β3-adrenoceptors expressed in Chinese hamster ovary cells (CHO-K1-β3) or endogenously expressed in 3T3-F442A adipocytes or ileum. SR59230A displayed partial agonist properties compared with the β3-adrenoceptor agonist CL316243 [(R,R)-5-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl]-amino]-propyl]1,3-benzodioxole-2,2-dicarboxylate] in CHO-K1-β3 with the intrinsic activity increasing with the level of receptor expression. Functional affinity values for SR59230A at each level of receptor expression were in agreement with pKI values determined by binding. In cytosensor microphysiometer studies, SR59230A was a full agonist for increases in extracellular acidification rates (ECARs) at all levels of receptor expression, and antagonist actions were measurable only in medium- or low-expressing cells. In 3T3-F442A adipocytes, SR59230A antagonized CL316243-mediated increases of cAMP and had no agonist actions. However, in the cytosensor micro-physiometer, SR59230A (acting via β3-adrenoceptors) was an agonist with an intrinsic activity greater than CL316243. In mouse ileum, SR59230A relaxed smooth muscle, although concentration-response curves were biphasic. Relaxant effects were produced by concentrations that did not affect cAMP levels. Differences in tissue responses to SR59230A were not caused by major differences in expression of Gαs. ECAR responses were not affected by pretreatment of cells with pertussis toxin, indicating that signaling did not involve Gi. Therefore, SR59230A displays agonist and antagonist actions at the mouse β3-adrenoceptor. Because SR59230A only antagonized accumulation of cAMP in 3T3-F442A adipocytes yet in the same cells was an agonist for ECAR, cAMP-independent signaling pathways must mediate part of the agonist actions in the microphysiometer. The American Society for Pharmacology and Experimental Therapeutics ER -